Healthcare / BiotechnologyNasdaqCM
$81.02
-7.05 (-8.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-7.0M · quality 68.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
23/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$795M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-14.9%
↓Gross Margin
N/A
•Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.71x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-12.2M · FCF $-8.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Net Income | $-12.2M | $-12.2M | $-2.8M | $-7.4M | $-15.0M |
| EBITDA | $-13.9M | $-13.9M | $-2.7M | $-7.3M | $-15.0M |
| EPS | -1.78 | -1.78 | -0.65 | -1.98 | -6.06 |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | 0.02 | 0.01 | 0.01 |
| Current Ratio | 81.48 | 81.48 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-8.7M | $-8.7M | $-1.9M | $-7.0M | $-13.6M |
| Returns | |||||
| ROE | -14.9% | -14.9% | -50.6% | -111.7% | -141.9% |
| Valuation | |||||
| P/B | 6.79 | 6.79 | 0.90 | 0.83 | 1.25 |
| Growth & Yield | |||||
| EPS Growth | -173.8% | -173.8% | 67.2% | 67.3% | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+212.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.65 → -1.78
Residual
+212.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.